Scientific Evidence: CBD when administered topically has shown to rapidly decrease inflammation in experimental animal models. This reduction in inflammation results in a decrease correlated reduction in pain.
Clinical and Scientific Evidence References:
Baswan SM et al. Therapeutic Potential of Cannabidiol (CBD) for Skin Health and Disorders. Clinical Cosmetic and Investigational Dermatology 2020;13:927–42.
https://pubmed.ncbi.nlm.nih.gov/33335413/
Hammell DC et al. Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis. Eur J Pain 20 2016;936—48.
https://pubmed.ncbi.nlm.nih.gov/26517407/
Lodzki M et al. Cannabidiol-transdermal delivery and anti-inflammatory effect in a murine model. J Control Release 2003;93(3):377-87.
https://pubmed.ncbi.nlm.nih.gov/14644587/
Scientific Evidence: CBD when administered topically has shown to rapidly decrease inflammation in experimental animal inflammation models using a transcutaneous vehicle. CBD has shown to have effects at the molecular level to decrease inflammation through FAAH inhibition and indirect modulation of CB2 receptors, decrease in pro-inflammatory cytokine release, inhibiting T cell proliferation, and reducing migration and adhesion of immune cells among other biological pathways. This reduction in inflammation results in a correlated decrease reduction in pain as seen in the animal model.
Clinical and Scientific Evidence References:
Baswan SM et al. Therapeutic Potential of Cannabidiol (CBD) for Skin Health and Disorders. Clinical Cosmetic and Investigational Dermatology 2020;13:927–42.
https://pubmed.ncbi.nlm.nih.gov/33335413/
Hammell DC et al. Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis. Eur J Pain 20 2016;936—48.
https://pubmed.ncbi.nlm.nih.gov/26517407/
Lodzki M et al. Cannabidiol-transdermal delivery and anti-inflammatory effect in a murine model. J Control Release 2003;93(3):377-87.
https://pubmed.ncbi.nlm.nih.gov/14644587/
Recent Comments